These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28649601)

  • 41. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
    Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
    Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease.
    Dexter DT; Wells FR; Lees AJ; Agid F; Agid Y; Jenner P; Marsden CD
    J Neurochem; 1989 Jun; 52(6):1830-6. PubMed ID: 2723638
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Parkinson's disease multimodal imaging: F-DOPA PET, neuromelanin-sensitive and quantitative iron-sensitive MRI.
    Depierreux F; Parmentier E; Mackels L; Baquero K; Degueldre C; Balteau E; Salmon E; Phillips C; Bahri MA; Maquet P; Garraux G
    NPJ Parkinsons Dis; 2021 Jul; 7(1):57. PubMed ID: 34238927
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An introduction to the free radical hypothesis in Parkinson's disease.
    Olanow CW
    Ann Neurol; 1992; 32 Suppl():S2-9. PubMed ID: 1510376
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Time-Specific Pattern of Iron Deposition in Different Regions in Parkinson's Disease Measured by Quantitative Susceptibility Mapping.
    Fu X; Deng W; Cui X; Zhou X; Song W; Pan M; Chi X; Xu J; Jiang Y; Wang Q; Xu Y
    Front Neurol; 2021; 12():631210. PubMed ID: 34421781
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease.
    Scherfler C; Esterhammer R; Nocker M; Mahlknecht P; Stockner H; Warwitz B; Spielberger S; Pinter B; Donnemiller E; Decristoforo C; Virgolini I; Schocke M; Poewe W; Seppi K
    Brain; 2013 Oct; 136(Pt 10):3028-37. PubMed ID: 24014521
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meta-Analysis of Copper and Iron in Parkinson's Disease Brain and Biofluids.
    Genoud S; Senior AM; Hare DJ; Double KL
    Mov Disord; 2020 Apr; 35(4):662-671. PubMed ID: 31889341
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Somatic copy number gains of α-synuclein (SNCA) in Parkinson's disease and multiple system atrophy brains.
    Mokretar K; Pease D; Taanman JW; Soenmez A; Ejaz A; Lashley T; Ling H; Gentleman S; Houlden H; Holton JL; Schapira AHV; Nacheva E; Proukakis C
    Brain; 2018 Aug; 141(8):2419-2431. PubMed ID: 29917054
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New Progress on the Role of Glia in Iron Metabolism and Iron-Induced Degeneration of Dopamine Neurons in Parkinson's Disease.
    Xu H; Wang Y; Song N; Wang J; Jiang H; Xie J
    Front Mol Neurosci; 2017; 10():455. PubMed ID: 29403352
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis.
    Hirsch EC; Brandel JP; Galle P; Javoy-Agid F; Agid Y
    J Neurochem; 1991 Feb; 56(2):446-51. PubMed ID: 1988548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Iron-sulfur enzyme mediated mitochondrial superoxide toxicity in experimental Parkinson's disease.
    Liang LP; Patel M
    J Neurochem; 2004 Sep; 90(5):1076-84. PubMed ID: 15312163
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detecting dopaminergic neuronal degeneration using diffusion tensor imaging in a rotenone-induced rat model of Parkinson's disease: fractional anisotropy and mean diffusivity values.
    Liu LX; Du D; Zheng T; Fang Y; Chen YS; Yi HL; He QY; Gao DW; Shi QL
    Neural Regen Res; 2017 Sep; 12(9):1485-1491. PubMed ID: 29089995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Free-water imaging in Parkinson's disease and atypical parkinsonism.
    Planetta PJ; Ofori E; Pasternak O; Burciu RG; Shukla P; DeSimone JC; Okun MS; McFarland NR; Vaillancourt DE
    Brain; 2016 Feb; 139(Pt 2):495-508. PubMed ID: 26705348
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-α-synuclein Parkinson's disease mice.
    Badr M; McFleder RL; Wu J; Knorr S; Koprich JB; Hünig T; Brotchie JM; Volkmann J; Lutz MB; Ip CW
    J Neuroinflammation; 2022 Dec; 19(1):319. PubMed ID: 36587195
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Can mesenchymal stem cells reduce vulnerability of dopaminergic neurons in the substantia nigra to oxidative insult in individuals at risk to Parkinson's disease?
    Datta I; Bhonde R
    Cell Biol Int; 2012 Jul; 36(7):617-24. PubMed ID: 22417707
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trial of Deferiprone in Parkinson's Disease.
    Devos D; Labreuche J; Rascol O; Corvol JC; Duhamel A; Guyon Delannoy P; Poewe W; Compta Y; Pavese N; Růžička E; Dušek P; Post B; Bloem BR; Berg D; Maetzler W; Otto M; Habert MO; Lehericy S; Ferreira J; Dodel R; Tranchant C; Eusebio A; Thobois S; Marques AR; Meissner WG; Ory-Magne F; Walter U; de Bie RMA; Gago M; Vilas D; Kulisevsky J; Januario C; Coelho MVS; Behnke S; Worth P; Seppi K; Ouk T; Potey C; Leclercq C; Viard R; Kuchcinski G; Lopes R; Pruvo JP; Pigny P; Garçon G; Simonin O; Carpentier J; Rolland AS; Nyholm D; Scherfler C; Mangin JF; Chupin M; Bordet R; Dexter DT; Fradette C; Spino M; Tricta F; Ayton S; Bush AI; Devedjian JC; Duce JA; Cabantchik I; Defebvre L; Deplanque D; Moreau C;
    N Engl J Med; 2022 Dec; 387(22):2045-2055. PubMed ID: 36449420
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping.
    He N; Ling H; Ding B; Huang J; Zhang Y; Zhang Z; Liu C; Chen K; Yan F
    Hum Brain Mapp; 2015 Nov; 36(11):4407-20. PubMed ID: 26249218
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetics and iron in the systems biology of Parkinson's disease and some related disorders.
    Funke C; Schneider SA; Berg D; Kell DB
    Neurochem Int; 2013 Apr; 62(5):637-52. PubMed ID: 23220386
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mitochondrial iron dyshomeostasis and its potential as a therapeutic target for Parkinson's disease.
    Xiao Z; Wang X; Pan X; Xie J; Xu H
    Exp Neurol; 2024 Feb; 372():114614. PubMed ID: 38007207
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Co-Expression of Nogo-A in Dopaminergic Neurons of the Human Substantia Nigra Pars Compacta Is Reduced in Parkinson's Disease.
    Eyer GC; Di Santo S; Hewer E; Andereggen L; Seiler S; Widmer HR
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.